JP2019517588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517588A5 JP2019517588A5 JP2019516096A JP2019516096A JP2019517588A5 JP 2019517588 A5 JP2019517588 A5 JP 2019517588A5 JP 2019516096 A JP2019516096 A JP 2019516096A JP 2019516096 A JP2019516096 A JP 2019516096A JP 2019517588 A5 JP2019517588 A5 JP 2019517588A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- optionally substituted
- och
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 65
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 65
- 125000003118 aryl group Chemical group 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 31
- 229910052736 halogen Inorganic materials 0.000 claims 31
- 150000002367 halogens Chemical class 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 229910052799 carbon Inorganic materials 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 24
- 108091030071 RNAI Proteins 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 230000009368 gene silencing by RNA Effects 0.000 claims 20
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- -1 amino, hydroxyl Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000004043 oxo group Chemical group O=* 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- MJPPGVVIDGQOQT-UHFFFAOYSA-N 2-bromo-5-(2-bromo-2-nitroethenyl)furan Chemical compound [O-][N+](=O)C(Br)=CC1=CC=C(Br)O1 MJPPGVVIDGQOQT-UHFFFAOYSA-N 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 229930010555 Inosine Natural products 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- LCIYFINKFGDAHD-UHFFFAOYSA-N azepane;3-nitrobenzoic acid Chemical compound C1CCCNCC1.OC(=O)C1=CC=CC([N+]([O-])=O)=C1 LCIYFINKFGDAHD-UHFFFAOYSA-N 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003786 inosine Drugs 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003212 purines Chemical class 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 235000021092 sugar substitutes Nutrition 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022022652A JP7530927B2 (ja) | 2016-06-06 | 2022-02-17 | ５’－シクロ－ホスホン酸修飾ヌクレオチド |
| JP2024074835A JP2024097860A (ja) | 2016-06-06 | 2024-05-02 | ５’－シクロ－ホスホン酸修飾ヌクレオチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346304P | 2016-06-06 | 2016-06-06 | |
| US62/346,304 | 2016-06-06 | ||
| PCT/US2017/036108 WO2017214112A1 (en) | 2016-06-06 | 2017-06-06 | 5'-cyclo-phosphonate modified nucleotides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022652A Division JP7530927B2 (ja) | 2016-06-06 | 2022-02-17 | ５’－シクロ－ホスホン酸修飾ヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517588A JP2019517588A (ja) | 2019-06-24 |
| JP2019517588A5 true JP2019517588A5 (enExample) | 2020-07-16 |
| JP7028865B2 JP7028865B2 (ja) | 2022-03-02 |
Family
ID=60579042
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516096A Active JP7028865B2 (ja) | 2016-06-06 | 2017-06-06 | ５’－シクロ－ホスホン酸修飾ヌクレオチド |
| JP2022022652A Active JP7530927B2 (ja) | 2016-06-06 | 2022-02-17 | ５’－シクロ－ホスホン酸修飾ヌクレオチド |
| JP2024074835A Pending JP2024097860A (ja) | 2016-06-06 | 2024-05-02 | ５’－シクロ－ホスホン酸修飾ヌクレオチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022652A Active JP7530927B2 (ja) | 2016-06-06 | 2022-02-17 | ５’－シクロ－ホスホン酸修飾ヌクレオチド |
| JP2024074835A Pending JP2024097860A (ja) | 2016-06-06 | 2024-05-02 | ５’－シクロ－ホスホン酸修飾ヌクレオチド |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11078227B2 (enExample) |
| EP (1) | EP3464313A4 (enExample) |
| JP (3) | JP7028865B2 (enExample) |
| KR (2) | KR102639586B1 (enExample) |
| CN (2) | CN114736256B (enExample) |
| AU (3) | AU2017279512B2 (enExample) |
| CA (1) | CA3023764A1 (enExample) |
| EA (1) | EA201892285A1 (enExample) |
| IL (2) | IL290633B2 (enExample) |
| MX (2) | MX2018015109A (enExample) |
| TW (2) | TW202423483A (enExample) |
| WO (1) | WO2017214112A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114736256B (zh) * | 2016-06-06 | 2025-09-02 | 箭头药业股份有限公司 | 5’-环膦酸酯修饰核苷酸 |
| LT3607069T (lt) | 2017-04-05 | 2023-01-10 | Silence Therapeutics Gmbh | Produktai ir kompozicijos |
| SG11202003126VA (en) | 2017-10-04 | 2020-05-28 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and uses thereof |
| JP7592034B2 (ja) * | 2019-06-06 | 2024-11-29 | アビディティー バイオサイエンシーズ，インク． | 核酸ポリペプチド組成物およびその使用 |
| WO2022056266A2 (en) | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
| TW202242111A (zh) | 2020-12-18 | 2022-11-01 | 美商Ionis製藥公司 | 用於調節因子ｘｉｉ之化合物及方法 |
| AU2022254705A1 (en) | 2021-04-08 | 2023-10-05 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| KR20240014067A (ko) | 2021-05-28 | 2024-01-31 | 애로우헤드 파마슈티컬스 인코포레이티드 | 뮤신 5AC (MUC5AC)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법 |
| KR20240070519A (ko) | 2021-08-05 | 2024-05-21 | 사네진 바이오 유에스에이 인크. | 1'-알킬 개질된 리보스 유도체 및 사용 방법 |
| JP2024534502A (ja) | 2021-09-22 | 2024-09-20 | セーンジーン バイオ ユーエスエー インコーポレイティド | オリゴヌクレオチドのインビボ送達に使用するための２’－アルキル又は３’－アルキル修飾リボース誘導体 |
| EP4413015A1 (en) | 2021-10-05 | 2024-08-14 | Sanegene Bio USA Inc. | Polyhydroxylated cyclopentane derivatives and methods of use |
| KR20240169616A (ko) | 2022-02-22 | 2024-12-03 | 사네진 바이오 유에스에이 인크. | 5'-변형된 카르보시클릭 리보뉴클레오티드 유도체 및 사용 방법 |
| WO2023220561A1 (en) | 2022-05-09 | 2023-11-16 | Sanegene Bio Usa Inc. | Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof |
| EP4541804A1 (en) * | 2022-06-14 | 2025-04-23 | Rona Bioscience, Limited | Cyclic phosphonate-modified nucleotide |
| CN119730859A (zh) | 2022-06-15 | 2025-03-28 | 箭头药业股份有限公司 | 用于抑制超氧化物歧化酶1(SOD1)表达的RNAi剂、其组合物及使用方法 |
| EP4555088A1 (en) | 2022-07-11 | 2025-05-21 | Sanegene Bio USA Inc. | Optimized 2'- modified ribose derivatives and methods of use |
| CA3263391A1 (en) | 2022-08-05 | 2024-02-08 | Sanegene Bio Usa Inc | DOUBLE-STRANDED RNA TARGETING ANGIOTENSINOGEN (AGT) AND ITS METHODS OF USE |
| WO2024062413A1 (en) * | 2022-09-21 | 2024-03-28 | Janssen Biotech, Inc. | Novel stabilized nucleoside phosphates and analogues thereof |
| KR20250088573A (ko) | 2022-10-14 | 2025-06-17 | 사네진 바이오 유에스에이 인크. | C3을 표적화하는 소형 간섭 rna 및 그의 용도 |
| AU2023372784A1 (en) * | 2022-11-02 | 2025-05-15 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| EP4638743A2 (en) | 2022-12-19 | 2025-10-29 | Sanegene Bio USA Inc. | Small interfering rna targeting cfb and uses thereof |
| US20240309383A1 (en) | 2023-02-24 | 2024-09-19 | Suzhou Sanegene Bio Inc. | Small interfering rna targeting hbv and uses thereof |
| US20240309380A1 (en) | 2023-03-03 | 2024-09-19 | Sanegene Bio Usa Inc. | Small interfering rna targeting apoc3 and uses thereof |
| US12378558B2 (en) | 2023-03-21 | 2025-08-05 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use |
| AU2024244071A1 (en) * | 2023-04-06 | 2025-10-30 | Shanghai Argo Biopharmaceutical Co., Ltd. | Nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom |
| WO2024263915A2 (en) | 2023-06-21 | 2024-12-26 | Sanegene Bio Usa Inc. | Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof |
| US20250064939A1 (en) | 2023-07-24 | 2025-02-27 | Sanegene Bio Usa Inc. | Lipid-based enhancement agent for rna delivery and therapy |
| WO2025137384A1 (en) | 2023-12-20 | 2025-06-26 | Arrowhead Pharmaceuticals, Inc. | Methods and reagents for improved oligonucleotide synthesis |
| WO2025228441A2 (en) | 2024-04-30 | 2025-11-06 | Sanegene Bio Usa Inc. | Small interfering rna targeting inhbe and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9009980D0 (en) * | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| NZ262254A (en) | 1993-01-25 | 1997-10-24 | Hybridon Inc | Oligonucleotide analogue containing a ribonucleotide alkylphosphon(ate or thioate), gene repression |
| AU6449294A (en) | 1993-03-31 | 1994-10-24 | Sterling Winthrop Inc. | Novel 5'-substituted nucleosides and oligomers produced therefrom |
| KR100414936B1 (ko) | 1997-09-12 | 2004-01-13 | 엑시콘 에이/에스 | 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체 |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| US7637807B2 (en) * | 2004-04-29 | 2009-12-29 | Cfph, L.L.C. | System and method for mapping results from sporting events to game inputs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| BRPI0715375A2 (pt) | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| BRPI0811170B8 (pt) * | 2007-05-22 | 2021-05-25 | Arcturus Therapeutics Inc | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| US20110196141A1 (en) | 2009-09-07 | 2011-08-11 | Council Of Scientific & Industrial Research | Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides |
| ES2562817T3 (es) | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| EP3173419A1 (en) | 2010-04-28 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom |
| WO2011139699A2 (en) * | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | 5' modified nucleosides and oligomeric compounds prepared therefrom |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| MX2014001971A (es) | 2011-08-26 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(vinilester) para suministro de acido nucleico in vivo. |
| MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
| EP2958998B1 (en) | 2013-02-22 | 2017-12-27 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| CN109069529B (zh) | 2016-03-07 | 2021-08-20 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
| CN114736256B (zh) * | 2016-06-06 | 2025-09-02 | 箭头药业股份有限公司 | 5’-环膦酸酯修饰核苷酸 |
| CN109462981B (zh) | 2016-09-02 | 2023-07-07 | 箭头药业股份有限公司 | 靶向配体 |
| KR20240096846A (ko) * | 2017-01-10 | 2024-06-26 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-1 항트립신 (AAT) RNAi 작용제, AAT RNAi 작용제를 포함하는 조성물, 및 사용 방법 |
-
2017
- 2017-06-06 CN CN202210360585.2A patent/CN114736256B/zh active Active
- 2017-06-06 JP JP2019516096A patent/JP7028865B2/ja active Active
- 2017-06-06 EA EA201892285A patent/EA201892285A1/ru unknown
- 2017-06-06 CN CN201780034726.9A patent/CN109526222B/zh active Active
- 2017-06-06 IL IL290633A patent/IL290633B2/en unknown
- 2017-06-06 WO PCT/US2017/036108 patent/WO2017214112A1/en not_active Ceased
- 2017-06-06 KR KR1020227025704A patent/KR102639586B1/ko active Active
- 2017-06-06 CA CA3023764A patent/CA3023764A1/en active Pending
- 2017-06-06 MX MX2018015109A patent/MX2018015109A/es unknown
- 2017-06-06 TW TW112132145A patent/TW202423483A/zh unknown
- 2017-06-06 EP EP17810836.1A patent/EP3464313A4/en active Pending
- 2017-06-06 AU AU2017279512A patent/AU2017279512B2/en active Active
- 2017-06-06 KR KR1020187034959A patent/KR102426487B1/ko active Active
- 2017-06-06 TW TW106118757A patent/TWI815794B/zh active
-
2018
- 2018-12-03 IL IL263437A patent/IL263437B/en unknown
- 2018-12-03 US US16/207,870 patent/US11078227B2/en active Active
- 2018-12-05 MX MX2023008478A patent/MX2023008478A/es unknown
-
2021
- 2021-06-30 US US17/363,983 patent/US12441756B2/en active Active
- 2021-11-10 AU AU2021266265A patent/AU2021266265A1/en not_active Abandoned
-
2022
- 2022-02-17 JP JP2022022652A patent/JP7530927B2/ja active Active
-
2023
- 2023-12-05 AU AU2023275805A patent/AU2023275805A1/en active Pending
-
2024
- 2024-05-02 JP JP2024074835A patent/JP2024097860A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517588A5 (enExample) | ||
| JP7169412B2 (ja) | 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体 | |
| JP6364472B2 (ja) | 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体 | |
| JP6814127B2 (ja) | 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット | |
| US9193719B2 (en) | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP6923543B2 (ja) | Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール | |
| AU2008244490B2 (en) | 6-phenylpyrimidinones as PIM modulators | |
| CN103848876B (zh) | 一种核苷磷酰胺前药及其制备方法和其应用 | |
| JP2013532122A5 (enExample) | ||
| JP2009511504A5 (enExample) | ||
| CN101805299A (zh) | 作为葡糖激酶(glk)激活剂的苯甲酰氨基杂环化合物 | |
| US20140315917A1 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2004508365A (ja) | 抗細胞増殖薬としてのイミダゾロ−５−イル−２−アニリノ−ピリミジン類 | |
| JP2016523087A5 (enExample) | ||
| RU2010150615A (ru) | Пролекарства антагонистов а2в рецептора аденозина | |
| JP2018532764A (ja) | ＧａｌＮＡｃクラスターホスホロアミダイト | |
| JP2020517677A5 (enExample) | ||
| CN110177780B (zh) | 含有酸性基团的嘧啶化合物 | |
| CN109790158A (zh) | 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途 | |
| JP2010518146A (ja) | ベンゾフラン化合物 | |
| CA2527315A1 (en) | Imidazole derivatives as glutamate receptor antagonists | |
| US8809357B2 (en) | Compounds and derivatizations of DNAs and RNAs on the nucleobases of pyrimidines for function, structure and therapeutics | |
| JPS63201127A (ja) | ５−フルオロウラシル誘導体を含有する制癌剤 | |
| US20190194746A1 (en) | Nucleic acid oligomer for rna hybrid formation | |
| CA2784153A1 (fr) | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 |